AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
CV Sciences, Inc.
Video analysis: CVSI
All videosNo video analysis for this stock yet. Request one from our team.
News: CVSI
CV Sciences Welcomes Enactment of Federal Legislation Providing Additional Time for a Responsible, Science-Based Hemp Regulatory Framework
Legislation delays implementation of new federal hemp restrictions until December 11, 2026, preserving continued access to naturally derived hemp products SAN DIEGO, CA / ACCESS Newswire / September 8, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today welcomed the enactment of federal legislation that delays implementation of significant changes to the federal definition of hemp and provides additional time for Congress and the Administration to develop a comprehensive regulatory framework for hemp-derived cannabinoid products. The legislation passed the U.S. House of Representatives by a bipartisan vote of 370-48 and the Senate by a vote of 90-6, President Trump signed the legislation into law on September 1.
CV Sciences (OTCMKTS:CVSI) Shares Cross Below 50 Day Moving Average – What’s Next?
CV Sciences, Inc. (OTCMKTS:CVSI - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $0.02 and traded as low as $0.0180. CV Sciences shares last traded at $0.0191, with a volume of 199,238 shares changing hands. CV Sciences
CV Sciences, Inc. (CVSI) Q2 2026 Earnings Call Transcript
CV Sciences, Inc. (CVSI) Q2 2026 Earnings Call Transcript
CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results
SAN DIEGO, CA / ACCESS Newswire / August 13, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2026. Second Quarter 2026 and Recent Financial, Operating and Regulatory Highlights Generated revenue of $3.0 million for the second quarter 2026 compared to $3.6 million for the second quarter 2025 and compared to $3.2 million for the first quarter 2026; Recognized gross margin of 48.6% for the second quarter 2026 compared to 50.9% for the second quarter 2025 and compared to 48.9% for the first quarter 2026; Cash balance of $0.3 million at quarter and year end; Reduced operating expenses by 11.3% to $1.7 million for the second quarter 2026 compared to $2.0 million for the second quarter 2025, and by 6.9% from $1.9 million in the first quarter 2026; Recognized an adjusted EBITDA loss of $0.1 million for the second quarter 2026 compared to positive adjusted EBITDA of $0.1 million for second quarter 2025 and compared to an adjusted EBITDA loss of $0.1 million for the first quarter 2026; Expanded the +PlusHLTH™ portfolio with personalized wellness solutions for healthy aging; Launched PlusHLTH.com, a new dedicated e-commerce platform strengthens the Company's strategy to build a leading science-backed health and wellness portfolio; and U.S. Senate voted 61-32 to approve Continuing Resolution H.R.
CV Sciences Launches PlusHLTH.com, Expanding Its Consumer Platform Beyond Cannabinoids
New digital destination brings the Company's Health Intelligence approach to life, helping consumers better understand their needs, discover science-backed solutions, and navigate healthy aging. SAN DIEGO, CA / ACCESS Newswire / August 11, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "our", "us" or "we"), a consumer health company specializing in science-backed natural ingredients and products, today announced the launch of PlusHLTH.com, a new direct-to-consumer destination dedicated exclusively to the Company's growing +PlusHLTH™ product line.
CV Sciences, Inc. to Announce Second Quarter 2026 Results on August 13, 2026
SAN DIEGO, CA / ACCESS Newswire / August 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the second quarter ended June 30, 2026, after the stock market closes on Thursday, August 13, 2026. The Company will hold a conference call with the investment community at 1:30 p.m.
CV Sciences Expands +PlusHLTH(TM) Portfolio with Personalized Wellness Solutions for Healthy Aging
Built on the Company's Health Intelligence™ Approach, the New Products Help Consumers Create Personalized Wellness Routines That Support Overall Health and Long-Term Vitality SAN DIEGO, CA / ACCESS Newswire / June 25, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a consumer wellness company specializing in science-backed natural ingredients and products, today announced the expansion of its +PlusHLTH™ supplement portfolio with additional formulations supporting cellular integrity, metabolism, cognitive health, cardiovascular wellness, and movement. Health Intelligence is CV Sciences' approach to personalized wellness, combining thoughtful formulations that support key areas of health targeting multiple pathways to support metabolism, brain health, cardiovascular wellness, movement, stress resilience, and vitality.
